Abstract:Epithelial‐mesenchymal transition (EMT) is a complex process with a primordial role in cellular transformation whereby an epithelial cell transforms and acquires a mesenchymal phenotype. This transformation plays a pivotal role in tumor progression and self‐renewal, and exacerbates resistance to apoptosis and chemotherapy. EMT can be initiated and promoted by deregulated oncogenic signaling pathways, hypoxia, and cells in the tumor microenvironment, resulting in a loss‐of‐epithelial cell polarity, cell–cell adhesion, and enhanced invasive/migratory properties. Numerous transcriptional regulators, such as Snail, Slug, Twist, and ZEB1/ZEB2 induce EMT through the downregulation of epithelial markers and gain‐of‐expression of the mesenchymal markers. Additionally, signaling cascades such as Wnt/β‐catenin, Notch, Sonic hedgehog, nuclear factor kappa B, receptor tyrosine kinases, PI3K/AKT/mTOR, Hippo, and transforming growth factor‐β pathways regulate EMT whereas they are often deregulated in cancers leading to aberrant EMT. Furthermore, noncoding RNAs, tumor‐derived exosomes, and epigenetic alterations are also involved in the modulation of EMT. Therefore, the regulation of EMT is a vital strategy to control the aggressive metastatic characteristics of tumor cells. Despite the vast amount of preclinical data on EMT in cancer progression, there is a lack of clinical translation at the therapeutic level. In this review, we have discussed thoroughly the role of the aforementioned transcription factors, noncoding RNAs (microRNAs, long noncoding RNA, circular RNA), signaling pathways, epigenetic modifications, and tumor‐derived exosomes in the regulation of EMT in cancers. We have also emphasized the contribution of EMT to drug resistance and possible therapeutic interventions using plant‐derived natural products, their semi‐synthetic derivatives, and nano‐formulations that are described as promising EMT blockers.

Regulation of EMT by Notch signaling pathway in tumor progression.

Notch Signaling Pathway Networks in Cancer Metastasis: a New Target for Cancer Therapy

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

Recent Researches on the Notch Signaling Pathway

Retraction Notice to “Notch-1 Induces Epithelial-mesenchymal Transition Consistent with Cancer Stem Cell Phenotype in Pancreatic Cancer Cells”

Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application

Activation of Notch Pathway is Linked with Epithelial-Mesenchymal Transition in Prostate Cancer Cells

The Functions of F-box Proteins in Regulating the Epithelial to Mesenchymal Transition.

Inhibition Of Notch Signaling Reverses Epithelial-Mesenchymal Transition In Esophageal Cancer

Down‐regulation of Notch‐1 and Jagged‐1 Inhibits Prostate Cancer Cell Growth, Migration and Invasion, and Induces Apoptosis Via Inactivation of Akt, Mtor, and NF‐κB Signaling Pathways

Novel insights into Notch signaling in tumor immunity: potential targets for cancer immunotherapy

Advances of NOTCH 1 Signaling in Cervical Cancer

Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds

Epigenetic Regulation of Epithelial to Mesenchymal Transition in the Cancer Metastatic Cascade: Implications for Cancer Therapy

The Role of MicroRNA in the Regulation of Tumor Epithelial–Mesenchymal Transition

Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells.

Regulation of the Notch signaling pathway by natural products for cancer therapy

Notch1 signaling regulates the epithelial–mesenchymal transition and invasion of breast cancer in a Slug-dependent manner

A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition

Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer

MicroRNAs target the Wnt/β-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer